gamma-aminobutyric acid has been researched along with Mucositis, Oral in 3 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "This pilot study is the first prospective randomized trial of gabapentin for RIM-related pain." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "To report a high incidence of oral mucosal dysesthesia occurring in patients on a pilot study of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck." | 9.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "Development of "burning"-type oral dysesthesia occurred in patients treated with the combination of gefitinib, paclitaxel, and external beam radiation of the oral tongue." | 9.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 8.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "No systematic reviews exist on the role of gabapentin for neuropathic pain in radiation-induced OM." | 8.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "Gabapentin was maintained at 900mg/day for 4 weeks after CRT." | 6.82 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Gabapentin (Neurontin) was administered to 2 patients as a treatment for painful mucosal neuropathy." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "All had stage III/IVA-B squamous cell carcinoma of the head and neck." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "The patients without grade 3 oral dysesthesia received less than 50 Gy radiation to the oral tongue." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "Development of "burning"-type oral dysesthesia occurred in patients treated with the combination of gefitinib, paclitaxel, and external beam radiation of the oral tongue." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "The oral dysesthesia was exacerbated by the ingestion of neutral pH liquids such as water." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "This dysesthesia was improved by the use of gabapentin." | 6.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "This pilot study is the first prospective randomized trial of gabapentin for RIM-related pain." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "To report a high incidence of oral mucosal dysesthesia occurring in patients on a pilot study of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck." | 5.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "Development of "burning"-type oral dysesthesia occurred in patients treated with the combination of gefitinib, paclitaxel, and external beam radiation of the oral tongue." | 5.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 4.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "No systematic reviews exist on the role of gabapentin for neuropathic pain in radiation-induced OM." | 4.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "Gabapentin was maintained at 900mg/day for 4 weeks after CRT." | 2.82 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Gabapentin (Neurontin) was administered to 2 patients as a treatment for painful mucosal neuropathy." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "All had stage III/IVA-B squamous cell carcinoma of the head and neck." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "The patients without grade 3 oral dysesthesia received less than 50 Gy radiation to the oral tongue." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "Development of "burning"-type oral dysesthesia occurred in patients treated with the combination of gefitinib, paclitaxel, and external beam radiation of the oral tongue." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "The oral dysesthesia was exacerbated by the ingestion of neutral pH liquids such as water." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "This dysesthesia was improved by the use of gabapentin." | 2.73 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kataoka, T | 1 |
| Kiyota, N | 1 |
| Shimada, T | 1 |
| Funakoshi, Y | 1 |
| Chayahara, N | 1 |
| Toyoda, M | 1 |
| Fujiwara, Y | 1 |
| Nibu, K | 1 |
| Komori, T | 1 |
| Sasaki, R | 1 |
| Mukohara, T | 1 |
| Minami, H | 1 |
| Milazzo-Kiedaisch, CA | 1 |
| Itano, J | 1 |
| Dutta, PR | 1 |
| Sharp, H | 1 |
| Morris, JC | 1 |
| Van Waes, C | 1 |
| Gius, D | 1 |
| Cooley-Zgela, T | 1 |
| Singh, AK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Phase I Dose Escalation Study Of The EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa) Combined With Paclitaxel (Taxol) And External Beam Radiation Therapy In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN)[NCT00083057] | Phase 1 | 30 participants (Anticipated) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gamma-aminobutyric acid and Mucositis, Oral
| Article | Year |
|---|---|
Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
2 trials available for gamma-aminobutyric acid and Mucositis, Oral
| Article | Year |
|---|---|
Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Carcinoma | 2016 |
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers.
Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2008 |